Lung cancer represents the largest cancer type segment in the UK Keytruda Market, valued between USD 800 million and USD 2.2 billion in 2024. Lung cancer is one of the most common cancers in the UK and a leading cause of cancer death. Keytruda has demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC), both as monotherapy and in combination with chemotherapy. As screening improves and treatment protocols evolve, demand for Keytruda in lung cancer is rising.

The UK Keytruda Market reflects lung cancer's dominance. Keytruda is approved for first-line and later-line treatment of NSCLC, and ongoing trials are exploring additional applications. The National Institute for Health and Care Excellence (NICE) has recommended Keytruda for certain lung cancer indications, improving access through the NHS. As lung cancer incidence rises and as immunotherapy becomes standard of care, demand for Keytruda is expected to grow.

Melanoma is the second-largest segment, valued between USD 300 million and USD 800 million in 2024, reflecting Keytruda's established role in treating advanced melanoma. Urothelial carcinoma and Hodgkin lymphoma are also significant segments, while stomach cancer is the fastest-growing, driven by increased awareness and new treatment protocols. As the UK Keytruda Market grows toward USD 5.32 billion by 2035, lung cancer is expected to remain the largest segment, driving overall market growth.

People Also Ask

• Why is lung cancer the largest segment?
  Lung cancer is one of the most common cancers in the UK, and Keytruda has demonstrated significant efficacy in treating NSCLC.

• What other cancers are treated with Keytruda in the UK?
  Keytruda is used to treat melanoma, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma, among others.

Tags: #LungCancer #Keytruda #UKHealthcare #Immunotherapy #Oncology #CancerTreatment